Selective inhibitors of type I receptor kinase block cellular transforming growth factor-β signaling
Rongrong Ge(Rutgers Cancer Institute), Michael Reiß(Klinikum Bremerhaven-Reinkenheide), Jit Chakravarty, Vaishali Rajeev(Rutgers Cancer Institute), Sundeep Dugar, Margaret Henson, George F. Schreiner, Glenn McEnroe, Gayathri Subramanian(Rutgers Cancer Institute), David Liu(University of Louisville), Kim A. Reiss(University of Pennsylvania), Linda S. Higgins, Alison Joly(Exelixis (United States))
Cited by 38
Related Papers
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
|Cell|2018|1.5k
Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
|Molecular Cancer Therapeutics|2011|1.3k
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
|Nature Medicine|2019|1.1k
Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors
|Nature Genetics|2018|701